- Home
- AVAX-USD vs QNTM Comparison
AVAX-USD vs QNTM Comparison
Compare AVAX-USD & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVAX-USD
- QNTM
- Stock Information
- Founded
- AVAX-USD N/A
- QNTM 1998
- Country
- AVAX-USD
- QNTM Canada
- Employees
- AVAX-USD N/A
- QNTM N/A
- Industry
- AVAX-USD
- QNTM
- Sector
- AVAX-USD
- QNTM
- Exchange
- AVAX-USD
- QNTM NYSE
- Market Cap
- AVAX-USD N/A
- QNTM 35.6M
- IPO Year
- AVAX-USD N/A
- QNTM N/A
- Fundamental
- Price
- AVAX-USD $18.18
- QNTM $21.72
- Analyst Decision
- AVAX-USD
- QNTM
- Analyst Count
- AVAX-USD 0
- QNTM 0
- Target Price
- AVAX-USD N/A
- QNTM N/A
- AVG Volume (30 Days)
- AVAX-USD N/A
- QNTM 417.9K
- Earning Date
- AVAX-USD N/A
- QNTM 08-13-2025
- Dividend Yield
- AVAX-USD N/A
- QNTM N/A
- EPS Growth
- AVAX-USD N/A
- QNTM N/A
- EPS
- AVAX-USD N/A
- QNTM N/A
- Revenue
- AVAX-USD N/A
- QNTM N/A
- Revenue This Year
- AVAX-USD N/A
- QNTM N/A
- Revenue Next Year
- AVAX-USD N/A
- QNTM N/A
- P/E Ratio
- AVAX-USD N/A
- QNTM N/A
- Revenue Growth
- AVAX-USD N/A
- QNTM N/A
- 52 Week Low
- AVAX-USD N/A
- QNTM $2.70
- 52 Week High
- AVAX-USD N/A
- QNTM $38.25
- Technical
- Relative Strength Index (RSI)
- AVAX-USD 40.25
- QNTM 54.19
- Support Level
- AVAX-USD $17.11
- QNTM $20.05
- Resistance Level
- AVAX-USD $18.47
- QNTM $38.25
- Average True Range (ATR)
- AVAX-USD 0.95
- QNTM 4.46
- MACD
- AVAX-USD 0.03
- QNTM -0.21
- Stochastic Oscillator
- AVAX-USD 44.11
- QNTM 35.18
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.